AllSci News
Lilly bets USD 800m on BioArctic’s blood-brain barrier platform for neurodegeneration
Sweden-based BioArctic AB (Nasdaq Stockholm: BIOA B) and Eli Lilly and Company have announced a research and collaboration agreement to combine BioArctic’s…
Regenxbio's Navsunli clears FDA path toward first gene therapy for Hunter syndrome
Rockville, Maryland-based REGENXBIO Inc. (Nasdaq: RGNX) has announced alignment with the US FDA on a path forward for resubmission of the Biologics License...
Nuvectis licenses Haisco's late-stage Factor B inhibitor and BRAF program in USD 1.4b deal
Fort Lee, New Jersey-based Nuvectis Pharma, Inc. (Nasdaq: NVCT) has signed an exclusive ex-China license agreement with China-based Haisco Pharmaceutical...
Regeneron seeking approval for cemdisiran as first siRNA therapy for generalized myasthenia gravis
Regulatory applications for cemdisiran, a small interfering RNA (siRNA) therapeutic targeting complement factor C5, have been accepted for review by both...
Harbour BioMed wins US verdict validating antibody discovery platform patent against Amgen
China-based Harbour BioMed (HKEX: 02142) has secured a unanimous jury verdict in the US District Court for the District of Delaware against…
AbbVie adds long-acting IL-13 assets in USD 10.9 billion Apogee acquisition
AbbVie (NYSE: ABBV) has agreed to acquire Apogee Therapeutics (Nasdaq: APGE) in an all-cash transaction valued at approximately USD 10.9 billion, adding a...
Greenstone-Intel collaboration highlights growing role of AI infrastructure in human-cell drug discovery
Palo Alto-based Greenstone Biosciences, Inc. and Intel Corporation have announced a strategic collaboration that brings one of the largest human induced pluripotent…
Insilico's USD 2.5 billion SK Biopharmaceuticals deal validates AI-first drug discovery at scale
Insilico Medicine (HKEX: 3696) has struck a neuroimmune drug discovery collaboration with South Korea-based SK Biopharmaceuticals (KRX: 326030.KS) worth up...
K2 Therapeutics commits up to USD 980m on masked TCE platform from Antengene
China-based Antengene Corporation Limited (HKEX: 6996) has licensed its preclinical CDH6 × CD3 bispecific T cell engager ATG-106 to K2 Therapeutics, a...
Memento launches with USD 93m to challenge anti-VEGF monopoly in retinal disease
Boston-based Memento Medicines, Inc. has launched with a USD 93 million Series A financing round to advance MMT-205 (previously known as MT-103), a...
Syntax Bio raises USD 14.4m to scale CRISPR-programmed cell therapy for type 1 diabetes
Chicago-based Syntax Bio has closed an expanded Series A totaling USD 14.4 million, bringing total funding to more than USD 25 million, as the synthetic...
SOPHiA Genetics raises USD 57.5 million to expand AI genomics platform beyond oncology
Switzerland-based SOPHiA GENETICS (Nasdaq: SOPH), an AI-native healthcare technology company, announced the closing of an underwritten public offering of...
Vanderbilt wins USD 1.77 million NIH grant to probe TBX4 pulmonary hypertension mechanisms
orglookupsummary note: The verified AllSci organization profile URL from orglookupsummary is...
CervoMed locks in neflamapimod exclusivity through 2042 with pure DLB patent strategy
Boston-based CervoMed Inc. (Nasdaq: CRVO) received a notice of allowance from the USPTO for a method-of-treatment patent protecting the use of neflamapimod…
Immunomic launches first self-amplifying RNA vaccine trial in triple-negative breast cancer
Privately held Rockville, Maryland-based Immunomic Therapeutics, Inc. has initiated a first-in-human Phase I trial of ITI-5000, a self-amplifying RNA...
The AllSci Brief
Free, systematic R&D and deal news. Daily.